Literature DB >> 12244204

Large and dissimilar repertoire of Melan-A/MART-1-specific CTL in metastatic lesions and blood of a melanoma patient.

Susanna Mandruzzato1, Elisabetta Rossi, Fabiola Bernardi, Valeria Tosello, Beatrice Macino, Giuseppe Basso, Vanna Chiarion-Sileni, Carlo Riccardo Rossi, Cristina Montesco, Paola Zanovello.   

Abstract

It is widely accepted that the repertoire of Melan-A-specific T cells naturally selected in melanoma patients is diverse and mostly nonoverlapping among different individuals. To date, however, no studies have addressed the TCR profile in different tumor sites and the peripheral blood from the same patient. We compared the TCR usage of Melan-A-specific T cells from different compartments of a single melanoma patient to evaluate possible clonotype expansion or preferential homing over a 4-mo follow-up period. Using HLA-A2 peptide tetramers, CD8(+) T cells recognizing the modified Melan-A immunodominant ELAGIGILTV peptide were isolated from four metastatic lesions resected from a single melanoma patient, and their TCR repertoire was studied. A panel of T cell clones was generated by cell cloning of tetramer-positive cells. Analysis of the TCR beta-chain V segment and the complementarity-determining region 3 (CDR3) length and sequence revealed a large diversity in the TCR repertoire, with only some of the clones showing a partial conservation in the CDR3. A similar degree of diversity was found by analyzing a number of T cell clones obtained after sorting a Melan-A-specific population derived from PBLs of the same patient after in vitro culture with the immunodominant epitope. Moreover, clonotypes found at one site were not present in another, suggesting the lack of expansion and circulation of one or more clonotypes. Taken together, these results buttress the notion that the CTLs recognizing the immunodominant Ag of Melan-A comprise a high number of different clonotypic TCR, of which only some exhibit common features in the CDR3.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12244204     DOI: 10.4049/jimmunol.169.7.4017

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  9 in total

1.  Identification of shared TCR sequences from T cells in human breast cancer using emulsion RT-PCR.

Authors:  Daniel J Munson; Colt A Egelston; Kami E Chiotti; Zuly E Parra; Tullia C Bruno; Brandon L Moore; Taizo A Nakano; Diana L Simons; Grecia Jimenez; John H Yim; Dmitri V Rozanov; Michael T Falta; Andrew P Fontenot; Paul R Reynolds; Sonia M Leach; Virginia F Borges; John W Kappler; Paul T Spellman; Peter P Lee; Jill E Slansky
Journal:  Proc Natl Acad Sci U S A       Date:  2016-06-15       Impact factor: 11.205

2.  Differential expression of constitutive and inducible proteasome subunits in human monocyte-derived DC differentiated in the presence of IFN-alpha or IL-4.

Authors:  Valeria Tosello; Rita Zamarchi; Anna Merlo; Margherita Gorza; Erich Piovan; Susanna Mandruzzato; Vincenzo Bronte; Xinhui Wang; Soldano Ferrone; Alberto Amadori; Paola Zanovello
Journal:  Eur J Immunol       Date:  2009-01       Impact factor: 5.532

Review 3.  Focus on TILs: prognostic significance of tumor infiltrating lymphocytes in human melanoma.

Authors:  Darryl A Oble; Robert Loewe; Ping Yu; Martin C Mihm
Journal:  Cancer Immun       Date:  2009-04-02

4.  Generation and immunosuppressive functions of p53-induced human adaptive regulatory T cells.

Authors:  Magis Mandapathil; Carmen Visus; Olivera J Finn; Stephan Lang; Theresa L Whiteside
Journal:  Oncoimmunology       Date:  2013-07-03       Impact factor: 8.110

5.  Analysis of cytotoxic T lymphocytes from a patient with hepatocellular carcinoma who showed a clinical response to vaccination with a glypican‑3‑derived peptide.

Authors:  Yoshitaka Tada; Toshiaki Yoshikawa; Manami Shimomura; Yu Sawada; Mayuko Sakai; Hirofumi Shirakawa; Daisuke Nobuoka; Tetsuya Nakatsura
Journal:  Int J Oncol       Date:  2013-07-31       Impact factor: 5.650

6.  Identification of a HLA-A*0201-restricted immunogenic epitope from the universal tumor antigen DEPDC1.

Authors:  Anna Tosi; Silvia Dalla Santa; Elisa Cappuzzello; Carolina Marotta; Dawid Walerych; Giannino Del Sal; Paola Zanovello; Roberta Sommaggio; Antonio Rosato
Journal:  Oncoimmunology       Date:  2017-04-05       Impact factor: 8.110

7.  TCR Analyses of Two Vast and Shared Melanoma Antigen-Specific T Cell Repertoires: Common and Specific Features.

Authors:  Sylvain Simon; Zhong Wu; J Cruard; Virginie Vignard; Agnes Fortun; Amir Khammari; Brigitte Dreno; Francois Lang; Samuel J Rulli; Nathalie Labarriere
Journal:  Front Immunol       Date:  2018-08-30       Impact factor: 7.561

Review 8.  TCR engineered T cells for solid tumor immunotherapy.

Authors:  Yikai Zhang; Zhipeng Liu; Wei Wei; Yangqiu Li
Journal:  Exp Hematol Oncol       Date:  2022-06-20

9.  Identification of a public CDR3 motif and a biased utilization of T-cell receptor V beta and J beta chains in HLA-A2/Melan-A-specific T-cell clonotypes of melanoma patients.

Authors:  Federico Serana; Alessandra Sottini; Luigi Caimi; Belinda Palermo; Pier Giorgio Natali; Paola Nisticò; Luisa Imberti
Journal:  J Transl Med       Date:  2009-03-24       Impact factor: 5.531

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.